首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

2126392

熱帶疾病診斷市場－策略分析與預測（2026-2035）

Tropical Disease Diagnostics Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月07日 | 出版商:

Knowledge Sourcing Intelligence | 英文 177 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計熱帶疾病診斷市場將從 2026 年的 58.3 億美元成長到 2035 年的 134.4 億美元，複合年成長率為 9.7%。

熱帶疾病診斷市場正經歷顯著的變革，其驅動力包括疾病監測計畫的擴展、地方性和新發熱帶病負擔的加重以及快速診斷檢測技術的日益普及。隨著醫療衛生系統和公共衛生機構認知到早期檢測在有效控制疾病和預防疫情爆發的重要性，市場發展呈現出向分散化、可近性和快速診斷解決方案轉變的趨勢。快速診斷檢測、分子診斷和數位監測平台的融合，使得熱帶疾病的檢測更加快速、方便且日益一體化。隨著疾病傳播區域的擴大以及各國政府將感染疾病防治列為優先事項，醫療衛生系統正不斷提升其診斷能力。透過即時檢測（PoC）平台、多分子檢測以及數位疾病監測整合的大量投資，熱帶疾病診斷正逐漸成為全球疫情防治和公共衛生領域的重要組成部分。

市場促進因素

疾病監測計畫的擴展是熱帶疾病診斷市場的主要驅動力。疾病控制工作依賴準確的診斷訊息，因為監測指南公共衛生干預措施。隨著熱帶病監測成為戰略重點，各國政府正在擴大檢測力度。疾病可視性不足限制了疫情防治工作。公共衛生機構正在加大對診斷基礎設施和檢查室網路的投資。加強監測正在推動市場需求，從而導致熱帶疾病診斷的使用量持續成長。地方性和新發熱帶病日益加重的疾病負擔，透過增加檢測需求，進一步加速了市場成長。熱帶疾病持續影響全部區域的數百萬人。隨著都市化和環境變遷影響疾病傳播模式，診斷需求不斷增加。隨著感染疾病在未加干預的情況下會迅速發展，及時診斷會影響治療效果。隨著醫療衛生系統擴大檢測範圍，快速診斷測試的應用也不斷增加。依賴傳統檢查室限制了醫療資源匱乏地區獲得診斷的機會。攜帶式檢測解決方案正在醫療保健項目中得到應用。可近性的提高正在推動市場成長。隨著分子診斷技術的日益普及，病原體鑑定的準確性和臨床可靠性也不斷提高。由於熱帶疾病的臨床症狀往往重疊，準確的病原體鑑定仍然至關重要。隨著診斷準確性變得日益重要，分子診斷技術正被檢查室廣泛採用。

市場限制因素

地方性流行區檢測基礎設施的匱乏限制了先進診斷技術的普及。在許多高發地區，由於缺乏足夠的設施和設備，先進診斷技術的擴充性受到限制。資金限制也影響高成本分子診斷技術的應用。先進技術所需的大量投資是發展中地區的一大障礙。熱帶疾病診斷方法的多樣性增加了檢測的複雜性，也增加了結果解讀的難度。熱帶疾病的臨床表現多種多樣，使得準確診斷變得困難。不同司法管轄區的監管差異也給尋求將新型診斷解決方案商業化的製造商帶來了合規方面的負擔。

依產品類型
- 裝置
- 試劑和試劑盒
- 快速診斷檢測（RDT）
- 軟體服務
依疾病類型
- 瘧疾
- 登革熱
- 基孔古尼亞
- 茲卡病毒感染疾病
- 利什曼原蟲症
- 南美錐蟲病
- 非洲錐蟲病
- 血吸蟲病
- 其他熱帶疾病
透過診斷方法
- 分子診斷
- 血清學檢測
- 快速診斷測試
- 顯微鏡檢查
- 次世代定序（NGS）
最終用戶
- 醫院
- 臨床檢查室
- 公共衛生研究所
- 學術研究機構
- 其他最終用戶

第10章：熱帶疾病診斷市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章：熱帶疾病診斷市場：國別分析

美國
加拿大
德國
英國
法國
印度
中國
泰國
印尼
菲律賓
巴西
墨西哥
哥倫比亞
奈及利亞
南非

第12章競爭格局

市佔率分析
策略趨勢
企業合併、商業夥伴關係和合作
新產品發布

第13章：公司簡介

Abbott Laboratories
F. Hoffmann-La Roche Ltd.
Danaher Corporation
bioMerieux SA
QIAGEN NV
Thermo Fisher Scientific Inc.
Bio-Rad Laboratories, Inc.
Siemens Healthineers AG
Sysmex Corporation
SD Biosensor, Inc.
Revvity, Inc.
OraSure Technologies, Inc.
Chembio Diagnostics, Inc.
Hologic, Inc.
Genetic Signatures Limited

第14章：熱帶疾病診斷市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009104

The Tropical Disease Diagnostics Market is anticipated to grow at a CAGR of 9.7% from USD 5.83 billion in 2026 to USD 13.44 billion in 2035.

The tropical disease diagnostics market is undergoing significant transformation driven by the expansion of disease surveillance programs, the rising burden of endemic and emerging tropical diseases, and the growing adoption of rapid diagnostic testing. The market's evolution is characterized by the shift toward decentralized, accessible, and rapid diagnostic solutions, as healthcare systems and public health agencies recognize the importance of early detection for effective disease control and outbreak prevention. The convergence of rapid diagnostic tests, molecular diagnostics, and digital surveillance platforms is enabling faster, more accessible, and increasingly integrated tropical disease detection. Healthcare systems are expanding diagnostic capabilities as disease transmission zones expand and governments prioritize infectious disease preparedness. The market is witnessing significant investment in point-of-care platforms, multiplex molecular assays, and digital disease surveillance integration, positioning tropical disease diagnostics as a critical component of global epidemic preparedness and public health.

Market Drivers

The expansion of disease surveillance programs represents the primary driver for the tropical disease diagnostics market. Disease control efforts depend on accurate diagnostic information because surveillance guides public health interventions. Governments are expanding testing initiatives as tropical disease monitoring becomes a strategic priority. Limited disease visibility constrains outbreak prevention efforts. Public health agencies are investing in diagnostic infrastructure and laboratory networks. Enhanced surveillance strengthens market demand, resulting in sustained growth in tropical disease diagnostic utilization. The rising burden of endemic and emerging tropical diseases is further accelerating market growth through increased testing demand. Tropical diseases continue affecting millions of individuals across endemic regions. Diagnostic demand is increasing as urbanization and environmental changes influence disease transmission patterns. Healthcare systems face pressure when infections spread beyond traditional risk zones. Providers are expanding diagnostic capacity to improve disease management. Growing disease burden supports market expansion. The adoption of rapid diagnostic testing is expanding testing accessibility in resource-constrained settings. Timely diagnosis influences treatment outcomes because many tropical diseases progress quickly without intervention. Rapid diagnostic tests are gaining adoption as healthcare systems seek broader testing accessibility. Conventional laboratory dependence limits diagnostic reach in underserved areas. Healthcare programs are deploying portable testing solutions. Increased accessibility supports market growth. Increasing molecular diagnostic integration is improving pathogen identification accuracy and clinical confidence. Precise pathogen identification remains essential because clinical symptoms frequently overlap across tropical diseases. Laboratories are adopting molecular diagnostics as diagnostic accuracy becomes increasingly important.

Market Restraints

Limited laboratory infrastructure in endemic regions restricts access to advanced diagnostics. The lack of adequate facilities and equipment in many high-burden regions limits the scalability of advanced diagnostics. Funding constraints affect implementation of high-cost molecular diagnostic technologies. The significant financial investment required for advanced technologies creates barriers for developing regions. Diagnostic variability across tropical diseases increases testing complexity and interpretation challenges. The diverse clinical manifestations of tropical diseases can complicate accurate diagnosis. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Technology and Product Insights

The technology landscape is characterized by the growing importance of integrated diagnostic ecosystems combining rapid testing, molecular platforms, and digital surveillance. Rapid diagnostic tests represent a major demand segment because they provide accessible testing in resource-constrained settings. Testing utilization is increasing as public health programs seek broader population coverage. Reagents and kits continue experiencing strong demand because molecular diagnostics adoption is expanding. Instruments remain essential for centralized laboratory operations. Software and services are becoming increasingly important because disease surveillance programs require integrated data management. The segment analysis reveals that malaria remains the largest diagnostic category because endemic regions require continuous screening and surveillance. Dengue fever testing demand is increasing as outbreaks affect larger populations across tropical and subtropical geographies. Chikungunya and Zika diagnostics continue gaining importance because symptom overlap creates diagnostic uncertainty. Neglected tropical diseases such as leishmaniasis, Chagas disease, African trypanosomiasis, and schistosomiasis continue requiring targeted diagnostic support. Rapid diagnostic testing remains widely utilized because it supports decentralized disease management. Molecular diagnostics adoption is increasing because healthcare providers require greater sensitivity and specificity. Public health laboratories represent a critical end-user segment, with hospitals and clinical laboratories expanding testing capabilities. The integration of digital surveillance is becoming increasingly important because disease control increasingly depends on real-time reporting and outbreak monitoring. Technology providers are developing connected diagnostic ecosystems.

Competitive and Strategic Outlook

The competitive landscape features established diagnostics and life science companies alongside specialized rapid test, molecular, and public health providers. Abbott remains strategically distinct because it combines rapid diagnostics expertise with extensive global healthcare reach, supporting infectious disease testing through portable and laboratory-based diagnostic solutions. Roche leverages molecular diagnostics leadership to support infectious disease surveillance and pathogen identification, focusing on automation, scalability, and analytical performance. Danaher participates through multiple diagnostic businesses supporting infectious disease management, with technological diversity and continuous innovation strengthening market relevance. bioMerieux maintains a strong position in infectious disease diagnostics through microbiology and molecular testing expertise, supporting laboratory workflows and disease surveillance activities. QIAGEN differentiates itself through molecular testing and sample preparation technologies, continuing to expand infectious disease assay offerings. Thermo Fisher benefits from extensive laboratory and molecular diagnostics capabilities, supporting disease surveillance and pathogen detection through broad technology offerings. Bio-Rad provides molecular diagnostic technologies supporting infectious disease testing. Siemens Healthineers leverages healthcare technology expertise and extensive laboratory diagnostics infrastructure. Companies are pursuing product portfolio expansion through innovation in multiplex molecular assays, rapid diagnostic tests, and digital surveillance platforms. Strategic collaborations between diagnostic manufacturers, public health agencies, and research institutions are increasing, driven by the need for outbreak preparedness and surveillance. Recent key developments include altona Diagnostics launching the RealStar Bundibugyo Virus RT-PCR Kit for specific detection of Bundibugyo virus RNA to support filovirus research and outbreak-related investigation workflows. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific, Africa, and Latin American markets where tropical disease burden is highest.

Short Conclusion

The tropical disease diagnostics market is positioned for sustained growth driven by the convergence of disease burden, surveillance expansion, and technological innovation. The transition from centralized laboratory testing toward integrated rapid and molecular diagnostic ecosystems represents a fundamental shift in infectious disease management. While challenges related to infrastructure limitations, funding constraints, and diagnostic variability persist, strategic investments in technology, partnerships, and surveillance integration are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with tropical disease diagnostics evolving into a critical component of global epidemic preparedness, supporting rapid detection, surveillance, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Tropical Disease Diagnostics Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Overview of Tropical Diseases
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Disease Burden & Unmet Diagnostic Needs
3.6 Epidemiology and Prevalence Analysis
3.7 Diagnosed Patient Population Analysis
3.8 Testing Volume Analysis
3.9 Disease Surveillance and Screening Analysis
3.10 Patient Journey and Diagnostic Pathway Assessment
3.11 Historical Market Size Analysis (2021-2025)
3.12 Market Forecast Analysis (2026-2035)

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Diagnostic Technologies
6.2 Product Innovation Analysis
6.3 Clinical Trial Analysis
6.4 Pipeline Analysis
6.5 Technology Roadmap
6.6 AI Integration in Tropical Disease Diagnostics
6.7 Point-of-Care Diagnostic Innovation Analysis
6.8 Digital Health and Disease Surveillance Integration

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Tropical Disease Diagnostics Market Landscape Analysis

8.1 Analysis by Technology Platform
8.2 Analysis by Biomarker Type
8.3 Analysis by Sample Type
8.4 Analysis by Disease Application
8.5 Analysis by Testing Methodology

9. Tropical Disease Diagnostics Market Segment Analysis (2021-2035)

9.1 By Product Type
- 9.1.1 Instruments
- 9.1.2 Reagents & Kits
- 9.1.3 Rapid Diagnostic Tests (RDTs)
- 9.1.4 Software & Services
9.2 By Disease Type
- 9.2.1 Malaria
- 9.2.2 Dengue Fever
- 9.2.3 Chikungunya
- 9.2.4 Zika Virus Disease
- 9.2.5 Leishmaniasis
- 9.2.6 Chagas Disease
- 9.2.7 African Trypanosomiasis
- 9.2.8 Schistosomiasis
- 9.2.9 Other Tropical Diseases
9.3 By Diagnostic Method
- 9.3.1 Molecular Diagnostics
- 9.3.2 Serological Testing
- 9.3.3 Rapid Diagnostic Testing
- 9.3.4 Microscopy-Based Testing
- 9.3.5 Next-Generation Sequencing (NGS)
9.4 By End User
- 9.4.1 Hospitals
- 9.4.2 Clinical Laboratories
- 9.4.3 Public Health Laboratories
- 9.4.4 Academic & Research Institutes
- 9.4.5 Other End Users